Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2008, Vol. 2 Issue (2) : 174-177
Modulatory effect on dyslipidemia and anti-atherosclerotic function of in newly diagnosed type 2 diabetes patients
SUN Mingxiao, WANG Yao, CHI Jiamin
Department of Endocrinology & Metabolism, Beijing Hospital, Ministry of Healthy
 Download: PDF(81 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract The modulatory effect of Xuezhikang on dyslipidemia and the preventive effect on atherosclerosis in newly diagnosed type 2 diabetic patients were studied. A prospective clinical trial was conducted to test the effectiveness of Xuezhikang in selected 201 newly diagnosed type 2 diabetic patients. All patients were randomly divided into two groups: 108 with Xuezhikang therapy and 93 without Xuezhikang therapy. The mean follow-up period was 22 months. The blood glucose and blood pressure of all patients were under control. Serum levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) were significantly lowered and their decreased percentages were significantly higher in Xuezhikang therapy group (P < 0.05). The number of patients with arteria iliaca intima thickening was significantly lower in group of Xuezhikang therapy (P = 0.024). With stepwise multivariate logistic regression analysis, the decreased percentage of TG was significantly and independently related with the decreased number of patients with arteria iliaca intima thickening (P = 0.005). The study demonstrates that Xuezhikang therapy is effective on modulating dyslipidemia in newly diagnosed type 2 diabetes patients, and may be related with the improvement of early atherosclerosis.
Issue Date: 05 June 2008
 Cite this article:   
WANG Yao,SUN Mingxiao,CHI Jiamin. Modulatory effect on dyslipidemia and anti-atherosclerotic function of in newly diagnosed type 2 diabetes patients[J]. Front. Med., 2008, 2(2): 174-177.
1 Stevens R J Kothari V Adler A I Stratton I M United Kingdom Prospective Diabetes Study(UKPDS) Group. TheUKPDS risk engine: a model for the risk of coronary heart diseasein Type II diabetes (UKPDS 56)Clin Sci(Lond) 2001 101(6)671679
2 Lu Z L Du B M Chen Z H Wu Y F Yu X H Zhao Y C (representthe effect of Xuezhikang regulatingthe blood fat to China Coronary Secondary Prevention Study Collaborativegroup). China Coronary Secondary Prevention Study (CCSPS)-analysisresult of patients with type 2 diabetes.Zhonghua Xin Xue Guan Bing Za Zhi 2005 33(2)10671070(in Chinese)
3 Zhang M L Duan Z W Xie S M The Xuezhikang activecomponent studyZhongguo Xin Yao Za Zhi 1990 43(12)1624(in Chinese)
4 Chen Y C Zhao S P Liu L Liu M H Li Y L Influence of lipid-modulating therapy onhigh-fat diet induce endothelial dysfunction in patients with coronaryheart diseaseZhonghua Xin Xue Guan BingZa Zhi 2004 32(2)114117(in Chinese)
5 Xu B P Chen Y L Lu X The effect of Xuezhikang on oxidation of low density lipoproteins in virtoZhonghua Nei Ke Za Zhi 1999 38(8)520522(in Chinese)
6 Huang Y Chen Y Z Shi R F Deng G L Inhibitingeffects of Xuezhikang on Monocytesadhesion in the patients with hypercholesterolemiaZhongguo Dong Mai Ying Hua Za Zhi 2002 10(1)5355(in Chinese)
7 Wu Y J Yu H Qin X W Wang X Y Sun Y H Chen J L Kou W R Lu Z L Small dense low-density lipoprotein in different type ofhyperlipidimia: Effect of lipid-lowering therapyZhongguo Xun Huan Za Zhi 2002 17(6)431433(in Chinese)
8 Zhang P H Li P Han X N Zhang X C Chen L Y Inhibitory effect of Xuezhikang on matrix metalloproteinase-2 secreted by macrophageZhonghua Xin Xue Guan Bing Za Zhi 2001 29(8)497499(in Chinese)
9 Zhao S P Liu L Cheng Y C Li Y L Effect of Xuezhikang, a cholestin extract, on reflectingpostprandial triglyceridemia after a high-fat meal in patients withcoronary heart diseaseAtherosclerosis 2003 168(2)375380.
10 Zhao S P Lu Z L Du B M Chen Z Wu Y F Yu X H Zhao Y C Liu L Ye H J Wu Z H Xuezhikang, an extract of cholestin, reduces cardiovascular events in type2 diabetes patients with coronary heart disease: Subgroup analysisof patients with type 2 diabetes from China Coronary Secondary PreventionStudy (CCSPS)J Cardiovasc Pharmacol 2007 49(2)14.
11 Laakso M Diabetesand cardiovascular disease in type 2 diabetes: Challenge for treatmentand preventionJ Intern Med 2001 249(3)225235.
Full text